AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32036764 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental risk format
Number of subjects: 321
Study 32036764 — intervention group
Group type: COMPARATOR
Intervention: Total risk format
Number of subjects: 321
Study 35416361 — intervention group
Group type: EXPERIMENTAL
Intervention: LF3-4 biomarker based on serum phosphopeptide profiling
Number of subjects: 60
Study 35416361 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind validation of LF3-4 biomarker
Number of subjects: 60
Study 33390054 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted systolic blood pressure (per 10 mm Hg)
Number of subjects: 375256
Study 33390054 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted diastolic blood pressure (per 5 mm Hg)
Number of subjects: 375256
Study 35618379 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuffield Early Language Intervention (NELI) program, 20-week duration
Number of subjects: 1173
Study 35618379 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 1173
Study 33740757 — intervention group
Group type: COMPARATOR
Intervention: 5-cm EVD tunnel length (group A)
Number of subjects: 105
Study 33740757 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-cm EVD tunnel length (group B)
Number of subjects: 105
Study 33740757 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-cm EVD tunnel length (group C)
Number of subjects: 105
Study 32447799 — intervention group
Group type: EXPERIMENTAL
Intervention: EVOO-enriched diet
Number of subjects: 33
Study 33540180 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cycle of breathing technique
Number of subjects: 100
Study 33540180 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 100
Study 32522198 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intravenous metoprolol
Number of subjects: 191
Study 32522198 — intervention group
Group type: COMPARATOR
Intervention: Control group (no metoprolol)
Number of subjects: 191
Study 34895792 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 124
Study 33852720 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesamorelin
Number of subjects: 61
Study 33852720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 35139908 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 5 mg BID
Number of subjects: 0
Study 35139908 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib 10 mg BID
Number of subjects: 0
Study 35139908 — intervention group
Group type: EXPERIMENTAL
Intervention: adalimumab 40 mg every 2 weeks
Number of subjects: 0
Study 35139908 — intervention group
Group type: COMPARATOR
Intervention: placebo switching to tofacitinib 5 mg BID
Number of subjects: 0
Study 35139908 — intervention group
Group type: COMPARATOR
Intervention: placebo switching to tofacitinib 10 mg BID
Number of subjects: 0
Study 35139908 — intervention group
Group type: COMPARATOR
Intervention: other groups (tofacitinib 10 mg BID, adalimumab)
Number of subjects: 0
Study 35139908 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib/adalimumab groups
Number of subjects: 0
Study 33871602 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet intervention
Number of subjects: 0
Study 35276669 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Number of subjects: 645
Study 35276669 — intervention group
Group type: COMPARATOR
Intervention: Postoperative chemoradiotherapy (CRT)
Number of subjects: 645
Study 35276669 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HRQoL measures (social functioning, nausea, WHO performance status, histologic subtype)
Number of subjects: 645
Study 34794789 — intervention group
Group type: EXPERIMENTAL
Intervention: SÜPEVAC unit
Number of subjects: 22
Study 34794789 — intervention group
Group type: COMPARATOR
Intervention: Wall suction
Number of subjects: 22
Study 34431174 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention twice per week (20-30 min sessions for 10 weeks, 1000 trials; 400-600 min total)
Number of subjects: 29
Study 34431174 — intervention group
Group type: COMPARATOR
Intervention: Intervention once per week (20-30 min sessions for 10 weeks, 500 trials; 200-300 min total)
Number of subjects: 29
Study 34431174 — intervention group
Group type: EXPERIMENTAL
Intervention: All past tense allomorphs treated with the intervention
Number of subjects: 29
Study 32391709 — intervention group
Group type: EXPERIMENTAL
Intervention: Shamiri-Digital intervention
Number of subjects: 103
Study 32391709 — intervention group
Group type: COMPARATOR
Intervention: Study-skills control intervention
Number of subjects: 103
Study 35590144 — intervention group
Group type: EXPERIMENTAL
Intervention: Helping Hand (HH)
Number of subjects: 60
Study 35590144 — intervention group
Group type: EXPERIMENTAL
Intervention: GloReha (GR)
Number of subjects: 60
Study 35590144 — intervention group
Group type: EXPERIMENTAL
Intervention: GRHH (50% GR and 50% HH)
Number of subjects: 60
Study 35590144 — intervention group
Group type: COMPARATOR
Intervention: Conventional Treatment (CT)
Number of subjects: 60
Study 34098818 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Exercise + Kinesio Taping (PFME + KT)
Number of subjects: 0
Study 34098818 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Exercise + External Electrical Stimulation (PFME + ES)
Number of subjects: 0
Study 34098818 — intervention group
Group type: COMPARATOR
Intervention: Pelvic Floor Muscle Exercise (PFME)
Number of subjects: 0
Study 37597578 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib + fulvestrant + trastuzumab (N + F + T)
Number of subjects: 71
Study 37597578 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant alone
Number of subjects: 71
Study 37597578 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant + trastuzumab (F + T)
Number of subjects: 71
Study 34600130 — intervention group
Group type: EXPERIMENTAL
Intervention: ANICGM (non-invasive continuous glucose monitor)
Number of subjects: 15
Study 33395981 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-rhythm EEG neurofeedback (NFB)
Number of subjects: 36
Study 33395981 — intervention group
Group type: COMPARATOR
Intervention: Sham-control
Number of subjects: 36
Study 35680447 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusion imaging group (preoperative CTA and image fusion reconstruction)
Number of subjects: 56
Study 35680447 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative CTA and image fusion reconstruction)
Number of subjects: 56
Study 33628717 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis (75 mg three times a day)
Number of subjects: 52
Study 33628717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 35386013 — intervention group
Group type: EXPERIMENTAL
Intervention: FMXIN001 (intranasal powder-based naloxone formulation)
Number of subjects: 56
Study 35386013 — intervention group
Group type: COMPARATOR
Intervention: Narcan® (nasal liquid spray)
Number of subjects: 56
Study 33780806 — intervention group
Group type: EXPERIMENTAL
Intervention: Logotherapy (LT)
Number of subjects: 48
Study 33780806 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 48
Study 33780806 — intervention group
Group type: COMPARATOR
Intervention: Control group (basic information workshop)
Number of subjects: 48
Study 35581545 — intervention group
Group type: EXPERIMENTAL
Intervention: fremanezumab
Number of subjects: 0
Study 35581545 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 34498370 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) intervention
Number of subjects: 13447
Study 34498370 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 13447
Study 33615766 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror cross education
Number of subjects: 39
Study 33615766 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinetic chain approach
Number of subjects: 39
Study 33615766 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 34836120 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Immersion (DI) for 5 days
Number of subjects: 14
Study 33742262 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc toothpaste (test)
Number of subjects: 212
Study 33742262 — intervention group
Group type: COMPARATOR
Intervention: Fluoride dentifrice (control)
Number of subjects: 212
Study 32035739 — intervention group
Group type: EXPERIMENTAL
Intervention: Home talks (HTs) delivered by village health workers (VHWs)
Number of subjects: 0
Study 32035739 — intervention group
Group type: COMPARATOR
Intervention: Control topics (randomly assigned)
Number of subjects: 0
Study 34231265 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiangnan Dietary pattern
Number of subjects: 502
Study 34231265 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 502
Study 32472417 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncotype DX recurrence score (RS) testing
Number of subjects: 3068
Study 32472417 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for MBC patients with low RS
Number of subjects: 3068
Study 32472417 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy for FBC patients with low RS
Number of subjects: 3068
Study 32472417 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall chemotherapy rates
Number of subjects: 3068
Study 86266805 — intervention group
Group type: EXPERIMENTAL
Intervention: R3: rifampin plus streptomycin plus isoniazid plus pyrazinamide daily for 3 months
Number of subjects: 694
Study 86266805 — intervention group
Group type: EXPERIMENTAL
Intervention: R5: rifampin plus streptomycin plus isoniazid plus pyrazinamide daily for 3 months followed by streptomycin plus isoniazid plus pyrazinamide twice weekly for 2 months
Number of subjects: 694
Study 86266805 — intervention group
Group type: EXPERIMENTAL
Intervention: Z5: streptomycin plus isoniazid plus pyrazinamide twice weekly for 2 months without rifampin
Number of subjects: 694
Study 86266805 — intervention group
Group type: EXPERIMENTAL
Intervention: R3 and R5 series combined
Number of subjects: 694
Study 86266805 — intervention group
Group type: EXPERIMENTAL
Intervention: Z5
Number of subjects: 694
Study 33903977 — intervention group
Group type: EXPERIMENTAL
Intervention: Olweus Bullying Prevention Program (OBPP)
Number of subjects: 2755
Study 34051342 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ) - 70 ml dose per day for 20 days (12.5 mmol nitrate per day; n = 11)
Number of subjects: 22
Study 34051342 — intervention group
Group type: COMPARATOR
Intervention: Non-nitrate calorie matched control (n = 11)
Number of subjects: 22
Study 33291988 — intervention group
Group type: EXPERIMENTAL
Intervention: Music (fast-tempo, 140 bpm)
Number of subjects: 14
Study 33291988 — intervention group
Group type: COMPARATOR
Intervention: No music
Number of subjects: 14
Study 33291988 — intervention group
Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 14
Study 34043853 — intervention group
Group type: EXPERIMENTAL
Intervention: TD‐GCBT + TAU
Number of subjects: 1061
Study 34043853 — intervention group
Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 1061
Study 33104675 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymmetric learning framework for ghost imaging (GI)
Number of subjects: 0
Study 33104675 — intervention group
Group type: COMPARATOR
Intervention: GIDL with a symmetric loss function
Number of subjects: 0
Study 36105074 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhanced adherence counseling and point-of-care viral load monitoring
Number of subjects: 50
Study 36105074 — intervention group
Group type: COMPARATOR
Intervention: Routine care (laboratory-based VL monitoring and standard EAC)
Number of subjects: 50
Study 33113253 — intervention group
Group type: EXPERIMENTAL
Intervention: E&S (30-second sprints during prolonged low-intensity cycling)
Number of subjects: 12
Study 33113253 — intervention group
Group type: EXPERIMENTAL
Intervention: E&S
Number of subjects: 12
Study 33113253 — intervention group
Group type: COMPARATOR
Intervention: E&S and E
Number of subjects: 12
Study 32854537 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein/moderate-carbohydrate (HP/MCHO) meal
Number of subjects: 14
Study 32854537 — intervention group
Group type: COMPARATOR
Intervention: Low-protein/high-carbohydrate (LP/HCHO) meal
Number of subjects: 14
Study 35800026 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week online High-Intensity Interval Training (HIIT) program, 3 sessions per week
Number of subjects: 30
Study 35800026 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group
Number of subjects: 30
Study 32162174 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Families New York (HFNY)
Number of subjects: 942
Study 32162174 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 942
Study 36461695 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-urodynamic single-dose Levofloxacin (500 mg administered one hour before the urodynamic study)
Number of subjects: 126
Study 36461695 — intervention group
Group type: COMPARATOR
Intervention: Post-urodynamic Levofloxacin (500 mg once daily for three days following the urodynamic study)
Number of subjects: 126
Study 33325641 — intervention group
Group type: EXPERIMENTAL
Intervention: SNFtool and DIABLO integration in study 1
Number of subjects: 59
Study 33325641 — intervention group
Group type: EXPERIMENTAL
Intervention: SNF integration in studies 2 and 3
Number of subjects: 59
Study 33325641 — intervention group
Group type: EXPERIMENTAL
Intervention: DIABLO in studies 2 and 3
Number of subjects: 59
Study 32410398 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical mucus removal prior to intrauterine insemination
Number of subjects: 0
Study 32410398 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33599247 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 6 mg regime
Number of subjects: 62
Study 33599247 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 12 mg regime (given Q84 h for 2 weeks)
Number of subjects: 62
Study 33599247 — intervention group
Group type: COMPARATOR
Intervention: Control (Lopinavir/Ritonavir)
Number of subjects: 62
Study 33599247 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (both doses)
Number of subjects: 62
Study 34857843 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation-guided balloon Eustachian tuboplasty (BET)
Number of subjects: 31
Study 34857843 — intervention group
Group type: COMPARATOR
Intervention: Medical management (MM)
Number of subjects: 31
Study 36173481 — intervention group
Group type: EXPERIMENTAL
Intervention: High Na+ (60 mmol L-1 sodium)
Number of subjects: 11
Study 36173481 — intervention group
Group type: COMPARATOR
Intervention: Low Na+ (21 mmol L-1 sodium)
Number of subjects: 11
Study 33694346 — intervention group
Group type: EXPERIMENTAL
Intervention: Occipitoatlantal decompression (OA-D) for 5 minutes followed by 10 minutes of rest
Number of subjects: 28
Study 33694346 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (taVNS) for 15 minutes
Number of subjects: 28
Study 33694346 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTR) with 15 minutes of rest
Number of subjects: 28
Study 35101711 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored physiotherapy delivered over 6 months, including pelvic floor muscle training in clinic and at home.
Number of subjects: 0
Study 35101711 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app to aid motivation and monitoring.
Number of subjects: 0
Study 34050798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound group
Number of subjects: 80
Study 34050798 — intervention group
Group type: COMPARATOR
Intervention: Palpation group
Number of subjects: 80
Study 35679281 — intervention group
Group type: EXPERIMENTAL
Intervention: SWIS (School Based Social Work)
Number of subjects: 280
Study 35679281 — intervention group
Group type: COMPARATOR
Intervention: Comparison arm (schools without social workers)
Number of subjects: 280
Study 32398852 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous double-protocol therapy (intravitreal dexamethasone implant and ranibizumab)
Number of subjects: 46
Study 32398852 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab monotherapy
Number of subjects: 46
Study 32512517 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 DNA ≥3 log10 copies/million PBMC
Number of subjects: 2019
Study 32512517 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 RNA ≥5 log10 copies/ml
Number of subjects: 2019
Study 32512517 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 DNA levels ≥3 log10 copies/million PBMC (multivariate analysis)
Number of subjects: 2019
Study 32512517 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma HIV-1 RNA
Number of subjects: 2019
Study 35768119 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative carbohydrate-loading drinks (4×200 mL evening before surgery and 2×200 mL the morning of surgery) and early postoperative nutritional protein supplement drinks two times per day for 14 days
Number of subjects: 64
Study 35768119 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving an equivalent volume of water
Number of subjects: 64
Study 34476742 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped text resource
Number of subjects: 281
Study 34476742 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped video resource
Number of subjects: 281
Study 34476742 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture (control)
Number of subjects: 281
Study 32584754 — intervention group
Group type: EXPERIMENTAL
Intervention: Advertisement cue (taking control of one's future)
Number of subjects: 0
Study 32584754 — intervention group
Group type: EXPERIMENTAL
Intervention: Advertisement cue combination (financial security and taking control of one's future)
Number of subjects: 0
Study 32584754 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation to enroll
Number of subjects: 0
Study 32584754 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue processing
Number of subjects: 0
Study 33019807 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided paravertebral block
Number of subjects: 40
Study 33019807 — intervention group
Group type: COMPARATOR
Intervention: Thoracoscopic-guided paravertebral block
Number of subjects: 40
Study 33086160 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts-extended-release (MAS-ER), titrated up to 80 mg daily
Number of subjects: 0
Study 33086160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35247334 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical LHA510 administered twice a day for 8 weeks and then 3 times a day for the last 4 weeks
Number of subjects: 90
Study 35247334 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo) administered twice a day for 8 weeks and then 3 times a day for the last 4 weeks
Number of subjects: 90
Study 35247334 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical LHA510
Number of subjects: 90
Study 33994064 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight fast (0100 h–0600 h)
Number of subjects: 19
Study 33994064 — intervention group
Group type: COMPARATOR
Intervention: Usual dietary habits (control period)
Number of subjects: 19
Study 32164673 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial therapy (trimethoprim 160 mg/sulfamethoxazole 800 mg twice a day plus folic acid 5 mg daily or doxycycline 100 mg once daily if body weight is < 50 kg or 100 mg twice daily if ≥50 kg)
Number of subjects: 500
Study 32164673 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 500
Study 82110185 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 68
Study 82110185 — intervention group
Group type: COMPARATOR
Intervention: Clomethiazole
Number of subjects: 68
Study 35482217 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric elbow flexor exercise (EE)
Number of subjects: 11
Study 35482217 — intervention group
Group type: COMPARATOR
Intervention: Concentric exercise (CE)
Number of subjects: 11
Study 32331734 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 50
Study 32331734 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical exercise)
Number of subjects: 50
Study 34982157 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly saliva testing
Number of subjects: 592
Study 34982157 — intervention group
Group type: COMPARATOR
Intervention: Biweekly midturbinate swabbing
Number of subjects: 592
Study 34982157 — intervention group
Group type: COMPARATOR
Intervention: Weekly midturbinate swabbing
Number of subjects: 592
Study 33387236 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturalistic behavioral social skills intervention (SIMI)
Number of subjects: 0
Study 33417481 — intervention group
Group type: EXPERIMENTAL
Intervention: Early interdisciplinary supportive care (ESC) integrated into standard oncologic care
Number of subjects: 328
Study 33417481 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 328
Study 33184828 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned Cesarean Delivery (PCD)
Number of subjects: 343
Study 33184828 — intervention group
Group type: COMPARATOR
Intervention: Vaginal Delivery (PVD)
Number of subjects: 343
Study 34698931 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g TXA i.v. preoperatively
Number of subjects: 52
Study 34698931 — intervention group
Group type: COMPARATOR
Intervention: No TXA
Number of subjects: 52
Study 32880572 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months' trastuzumab
Number of subjects: 4088
Study 32880572 — intervention group
Group type: COMPARATOR
Intervention: 12 months' trastuzumab
Number of subjects: 4088
Study 36056882 — intervention group
Group type: EXPERIMENTAL
Intervention: FIRM-guided ablation
Number of subjects: 269
Study 36056882 — intervention group
Group type: COMPARATOR
Intervention: Conventional ablation
Number of subjects: 269
Study 34133089 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (5 mg)
Number of subjects: 7269
Study 34133089 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (10 mg)
Number of subjects: 7269
Study 34133089 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (15 mg)
Number of subjects: 7269
Study 34133089 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (20 mg)
Number of subjects: 7269